author-photo

Christopher W. Espelin

Pfizer

18

Papers

270

Citations

Citation Trend

Filter By

Papers (18) Sort By

Journal Conference Others

Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody Drug Conjugates to Increase In Vivo Efficacy.

2020 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (5)
Nanoliposome targeting in breast cancer is influenced by the tumor microenvironment

2019 Nanomedicine: Nanotechnology, Biology and Medicine
Show All
- Source
- Cite
- Save
Citations (12)
Abstract 215: Generation of site-specific DARPin® drug conjugates using EGFR as a model system

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract P4-21-40: In vitro and in vivo activity of HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 in HER2-intermediate tumors

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract P3-06-05: Receptor-mediated binding of HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 increases liposome binding, nuclear doxorubicin, DNA damage and efficacy relative to untargeted PEGylated liposomal doxorubicin (PLD/Doxil)

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Quantitative evaluation of HER2-mediated cellular uptake of the HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 suggests potential for treating HER2-intermediate tumors

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (63)
Abstract LB-061: HER2-targeted PEGylated liposomal doxorubicin (MM-302) efficiently targets the HER2 intermediate cell population in vitro and in vivo

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)

2015 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (42)
Abstract 4134: MM-302 is more effective than PEGylated liposomal doxorubicin (PLD) at reducing pulmonary metastatic burden in breast cancer models expressing intermediate levels of HER2

2015 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)